Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Aicure

Aicure

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments.

Based in New York, USA, AiCure was founded by Adam Hanina and Laura Shafner in 2010. AiCure is a data-analytics company that uses artificial intelligence to understand how patients respond and comply with medication treatments. The AI assists with patient/ provider decision-making and records patient outcomes. Additionally, AiCure developed a patented facial recognition and motion-sensing application; accessible by a front-facing smartphone camera, that tracks real-time medication compliance and ingestion. AiCure is funded by the National Institutes of Health (NIH) as well as investors. AiCure has over 65 patents and has expanded globally to over 30 countries.

AiCure uses artificial intelligence to see, hear, and understand how patients respond to treatment. Additionally, AiCure developed the aforementioned IMA, an interactive medical assistant, available via a smartphone with camera, to assist patients and ensure they receive treatment or follow medication compliance routine.

COVID-19 Response and Contribution:

COVID-19 is changing the way the industry thinks about preserving clinical trials while ensuring patient safety. AiCure enables continuity by providing remote and direct patient communication and engagement, ensuring assessments, medication adherence, virtual registration, training, and payments. Sites can continue to provide care and stay closely connected to their patients with a trusted provider of direct site and patient communication for a decade. AiCure is working with sites to maintain their patient relationship via video chat (telehealth) in a HIPAA and GDPR compliant manner while maintaining patient safety and privacy.

Timeline

April 28, 2020
AiCure Launches Platform to Remotely Capture Digital Biomarkers in Clinical Trials

November 8, 2019
AiCure has a post-money valuation in the range of $100M to $500M as of Nov 8, 2019 according to PrivCo.
November 7, 2019
Their latest funding was raised on Nov 7, 2019 from a Series C round. AiCure is funded by 11 investors. Singtel Innov8 and New Leaf Venture Partners are the most recent investors.
November 7, 2019
Aicure raises a $24,500,000 series C round.
November 7, 2019
Aicure raises a $24,500,000 series C round from Palisades Growth Capital.
November 2019
Aicure raises a $24,500,000 series C round from Accelmed Growth Partners, Asahi Kasei, Baird Capital, Biomatics Capital Partners, New Leaf Venture Partners, Palisades Growth Capital, Pritzker Group Venture Capital, Silicon Valley Bank, SingTel Innov8, Springrock Ventures and Tribeca Venture Partners.
November 2017
Aicure raises a $15,000,000 series B round from Baird Capital, Biomatics Capital Partners, New Leaf Venture Partners, Pritzker Group and Tribeca Venture Partners.
January 2015
Aicure raises a $12,300,000 series A round from Biomatics Capital Partners, New Leaf Venture Partners, Pritzker Group and Tribeca Venture Partners.

Funding rounds

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

AI-Enabled Drug Discovery & Clinical Trials Market 2020-2026 Increasing Drug Development Expenditure By Major Key Players: AiCure, LLC, Berkeley Lights, Inc., CytoReason, Exscientia Limited, Mind the Byte, Symphony Innovation, LLC - 3w Market News Reports

Web

June 22, 2020

AiCure | NIH SBIR/STTR

Web

August, 2016

AiCure's strategy of providing data for life sciences reinforced by record economic momentum

AiCure

Web

January 14, 2020

New Research Sheds Light on Intentional Non-adherence in Clinical Trials

Web

June 15, 2020

News

Title
Author
Date
Publisher
Description
AiCure
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- AiCure, an AI and data analytics company focused on improving clinical trials, and OncoBay Clinical, a full-service boutique contract research...

References

Golden logo
By using this site, you agree to our Terms & Conditions.